209 related articles for article (PubMed ID: 14630675)
1. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
Pace A; Vidiri A; Galiè E; Carosi M; Telera S; Cianciulli AM; Canalini P; Giannarelli D; Jandolo B; Carapella CM
Ann Oncol; 2003 Dec; 14(12):1722-6. PubMed ID: 14630675
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
Brada M; Viviers L; Abson C; Hines F; Britton J; Ashley S; Sardell S; Traish D; Gonsalves A; Wilkins P; Westbury C
Ann Oncol; 2003 Dec; 14(12):1715-21. PubMed ID: 14630674
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
4. Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
Koekkoek JA; Dirven L; Heimans JJ; Postma TJ; Vos MJ; Reijneveld JC; Taphoorn MJ
J Neurooncol; 2016 Jan; 126(2):347-54. PubMed ID: 26547911
[TBL] [Abstract][Full Text] [Related]
5. Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide.
Koekkoek JA; Dirven L; Heimans JJ; Postma TJ; Vos MJ; Reijneveld JC; Taphoorn MJ
J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):366-73. PubMed ID: 25055819
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up.
Villani V; Merola R; Vidiri A; Fabi A; Carosi M; Giannarelli D; Marucci L; Maschio M; Carapella CM; Pace A
Tumori; 2017 May; 103(3):255-260. PubMed ID: 27716874
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Silvani A; Eoli M; Salmaggi A; Lamperti E; Maccagnano E; Broggi G; Boiardi A
J Neurooncol; 2004 Jan; 66(1-2):203-8. PubMed ID: 15015788
[TBL] [Abstract][Full Text] [Related]
8. Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Parlato C; Barbarisi M; Moraci M; Moraci A
Front Biosci; 2006 May; 11():1280-3. PubMed ID: 16368514
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide after radiotherapy in recurrent "low grade" diffuse brainstem glioma in adults.
Reyes-Botero G; Laigle-Donadey F; Mokhtari K; Martin-Duverneuil N; Delattre JY
J Neurooncol; 2014 Dec; 120(3):581-6. PubMed ID: 25139026
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Brandes AA; Ermani M; Basso U; Amistà P; Berti F; Scienza R; Rotilio A; Pinna G; Gardiman M; Monfardini S
Ann Oncol; 2001 Feb; 12(2):255-7. PubMed ID: 11300334
[TBL] [Abstract][Full Text] [Related]
11. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
[TBL] [Abstract][Full Text] [Related]
13. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
[TBL] [Abstract][Full Text] [Related]
14. Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.
Roelcke U; Wyss MT; Nowosielski M; Rudà R; Roth P; Hofer S; Galldiks N; Crippa F; Weller M; Soffietti R
Neuro Oncol; 2016 May; 18(5):744-51. PubMed ID: 26578622
[TBL] [Abstract][Full Text] [Related]
15. Rechallenge temozolomide in glioma: A case series from India.
Patil VM; Tonse R; Kothari R; Chandrasekaran A; Pande N; Epari S; Gupta T; Jalali R
Indian J Cancer; 2017; 54(1):368-371. PubMed ID: 29199725
[TBL] [Abstract][Full Text] [Related]
16. When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
Huang F; Kavan P; Guiot MC; Markovic Y; Roberge D
Can J Neurol Sci; 2008 May; 35(2):192-7. PubMed ID: 18574933
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in low-grade glioma patients receiving temozolomide.
Liu R; Solheim K; Polley MY; Lamborn KR; Page M; Fedoroff A; Rabbitt J; Butowski N; Prados M; Chang SM
Neuro Oncol; 2009 Feb; 11(1):59-68. PubMed ID: 18713953
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide in children with progressive low-grade glioma.
Gururangan S; Fisher MJ; Allen JC; Herndon JE; Quinn JA; Reardon DA; Vredenburgh JJ; Desjardins A; Phillips PC; Watral MA; Krauser JM; Friedman AH; Friedman HS
Neuro Oncol; 2007 Apr; 9(2):161-8. PubMed ID: 17347491
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach.
Perry JR; Rizek P; Cashman R; Morrison M; Morrison T
Cancer; 2008 Oct; 113(8):2152-7. PubMed ID: 18756530
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Verhoeff JJC; Lavini C; van Linde ME; Stalpers LJA; Majoie CBLM; Reijneveld JC; van Furth WR; Richel DJ
Ann Oncol; 2010 Aug; 21(8):1723-1727. PubMed ID: 20064829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
